- In June 2024, The Società Italiana di Neurologia launched the Italian Brain Health Strategy 2024-2031 to raise awareness and address mental and neurological diseases. Aligned with the WHO’s Global Action Plan, it promotes collaboration between patients, healthcare providers, and policymakers, focusing on enhancing brain health for all demographics in Italy over the next decade
- In August 2023, NURAMI MEDICAL announced the FDA 510(k) clearance for its ArtiFascia Dura Substitute, a breakthrough in neurosurgery. Made from electrospun nanofibers, this innovative graft aids in dural repair, promotes tissue regeneration, prevents cerebrospinal fluid (CSF) leakage, and ensures ease of use. It marks a significant advancement in surgical technology for improving patient outcomes
- In May 2022, The WHO adopted the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders (2022-2031) to improve treatment access and the quality of life for those affected by neurological disorders. This strategic plan outlines objectives in governance, diagnosis, prevention, research, and public health to address epilepsy and similar conditions worldwide
